ZD 1839 in patients with brain metastases from non-small-cell lung cancer (NSCLC): report of four cases.
The activity of ZD 1839 on brain metastases (BM) from Non-Small-Cell Lung Cancer (NSCLC) is unknown. We report four cases of BM responding to ZD 1839 theraphy.
Cappuzzo
F
F
Division of Medical Oncology, Bellaria Hospital, Via Altura 3, 40139 Bologna, Italy. federico.cappuzzo@ausl.bo.it
Calandri
C
C
Bartolini
S
S
Crinò
L
L
D000368:Aged; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy / Q000556:secondary*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000532:radiotherapy / Q000556:secondary*; D005260:Female; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D011799:Quinazolines / Q000494:pharmacology*; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D011799:Quinazolines; D000077156:Gefitinib